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Abstract
Aim. To assess the levels of markers of the bone synthesis and system inflammation in patients with osteoarthritis (OA) in com-
bination with obesity and their dynamic under the influence of basic treatment. 
Materials and methods. The research included 40 women with OA, 46–78 years old (mean age – 59,8±1,5 years). Du-
ration of the disease varied from 3 to 36 years (mean duration – 10,0±1,1 years). Mean body mass index (BMI) among patients 
was 30,6±0,7 [22,3; 39,5] kg/m2, according to which patients were divided in 3 groups: patients with OA without obesity (n=17), 
patients with OA with 1 degree of obesity (n=14), patients with OA with 2 degree of obesity (n=9). The level of osteochon-
dral metabolism was assessed using quantitative measuring of the levels of procollagen IC-terminal propeptide (РІСР), (Cloud- 
CloneCorp. “procollagen IC-Terminal Propeptide”, USA) and osteocalcin (Roche Diagnostics «N-MID Osteocalcin», Switzer-
land) on analyzer «ELECSYS 2010» by the method of immune-enzyme analysis; the level of the system inflammation was as-
sessed by the level of C-reactive protein (CRP) by the method of immunoturbidimetry. The clinical efficacy was assessed by the 
dynamics of intensity levels of pain syndromes at physical load and at rest by the visual-analogue scale (VAS). The measuring of 
РІСР, osteocalcin and CRP levels and also the assessment of clinical efficacy as to the decrease of pain syndrome were carried out 
twice – at the beginning and at the end of observation. The period of observation is 2 months. 
Results. The presence of direct correlation between РІСР and BMI (r=0,62; р=0,008) among patients with OA in combination 
with the normal body weight was established at the research, whereas among patients with OA in combination with obesity the anal-
ogous correlation was demonstrated between SRP and BMI (r=0,43; р=0,04) on the background of correlation of PICP and OC levels 
(r=0,46; р=0,03). 
Obesity in patients with OA was associated with the reliably higher levels of pain at both rest and physical load from the side of 
knee joints, with maximal intensity of the pain syndrome among patients with OA and 1 degree of obesity. 
Statistical analysis did not reveal the reliable dependence of РІСР and OC in patients with OA from the initial CRP level on 
the background of tendency to the higher РІСР level and lower OC level among patients with initially increased CRP level comparing 
with ones with normal CRP level. The therapy with basic preparations at OA during 2 months among patients with OA with increased 
CRP level led to the reliable decrease of РІСР level (р=0,0076) and the tendency to increase of OC level (р˃0,05), without the reliably 
significant difference between the initial and final РІСР and OC levels among patients with OA and normal CRP level. 
At the end of observation period the maximal analgesic effect was demonstrated as to the articulate pain at rest from the side of 
knee joints (р˂0,001) among patients with OA, who received diacerein, with clinically comparable effect from the side of other aticulate 
zones (р˂0,05), that was associated with reliable decrease of CRP level (р=0,013).
Discussion. The received results testify that the control of the system inflammation level at OA is a target not only relative to 
the decrease of pain syndrome but also conditions the stable state of subchondral bone (SCB), providing the compensation of processes 
of destruction and synthesis in bone tissue. The significance of procollagen IC-terminal propeptide (РІСР) and osteocalcin (OC) as the 
markers of bone synthesis that are able to reflect metabolic processes in SCB at OA, and also the discordant influence of CRP level on 
PICP level at the relative stability of OC level were demonstrated at the research. 
The received results allow consider the inflammatory process at OA as a target for preservance of the bone tissue, conditioning 
the expedience of taking into account the ability of OA basic preparations to realize the control influence on the level of system inflam-
mation. Diacerein that in ESCEO recommendations (2014) is related to the preparations of the 1 step of treatment of patients with OA 
provides the control on inflammation and stability of osteocalcin level that testifies to the balance of catabolic processes in SCB. 
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Conclusions. At OA the levels of procollagen IC-terminal propeptide (РІСР) and osteocalcin (OC) were not associated with 
obesity and did not depend on the initial CRP level at the presence of correlation between РІСР level and BMI among patients with OA 
with the normal body weight and BMI and CRP level among patients with OA in combination with obesity. 
The absence of reliable dynamics from РІСР side and maintenance of the stable OC level on the background of the reliable an-
ti-inflammatory effect at using diacerein in patients with OA can testify to the compensatory adequacy of reparation processes in SCB. 
Keywords: osteoarthritis, obesity, procollagen IC-terminal propeptide, osteocalcin, system inflammation, diacerein. 
DOI: 10.21303/2504-5679.2016.00175  © Anna Cherkasova, Olexander Kuryata
1. Introduction
According to the modern epidemiological data, osteoarthritis is the most frequent form of 
arthritis. According to WHO data, 25 % of adult population past 65 years old has clinically symp-
tomatic OA of one or other joint [1]. Besides persisting pain syndrome, OA is also the case of early 
disablement and high invalidism of population. 
The modern conception of OA considers this disease rather as abnormal remodeling of all 
articulate tissues (articulate cartilage, subchondral bone, synovial tunic, muscles, ligaments, me-
niscuci), conditioned by the influence of proinflammatory mediators, and not only as degenerative 
process, conditioned by age, as it was previously considered [2]. Thus, the understanding of OA 
must be the complex one and take into account not only clinical symptoms but also the degree of 
structural changes of all components of articulate cartilage that gives a possibility to assess the role 
of separate pathogenetic factors that have the cross influence on joint and also their contribution in 
OA progressing [3]. 
The question about, are the changes in subchondral bone (SCB) the primary ones as to the 
injury of cartilage or appear at further OA progressing, remains discussable one. The studies of last 
decades demonstrate that abnormal remodeling of SCB, namely subchondral osteosclerosis and 
formation of osteophytes that is conditioned by the appearance of new loci of osteogenesis often go 
before the changes in articulate cartilage and stenosis of articulate fissure [4–6]. The mediators of 
inflammation, which level in articulate cartilage increases at OA, can also lead to the destruction 
of subchondral bone at the expense of intensification of bone remodeling processes [7]. At the same 
time it is known that the system osteoporosis, attended with the decrease of bone tissue mass, has 
inducing influence and/or is able to result in OA progressing [8]. Thus, both phenotypes of the bone 
tissue remodeling (osteosclerosis and osteoporosis) can be considered as the risk factors of OA 
development. At that, the presence of other risk factors of OA leads to the synergetic influence as 
to OA initiation. 
It is known, that the balance between the bone synthesis and its resorption in SCB is broken 
at OA that on the background of metabolic processes [9] leads to the defective mineralization of 
bone and decrease of its biochemical properties [5, 10]. The distinctive feature of the bone tissue 
remodeling mechanisms at OA is the differences in domination of catabolic or anabolic component 
depending on the stage of OA development [11]. The study of osteocytes activity invitro demon-
strates the bone resorptions at the early OA stages [12, 13], with further decrease of their intensity 
at further OA progressing [14] that is proved by the results of several researches with measuring 
the level of bone creation and bone resorption markers in the blood serum of patients with OA [15]. 
The progressive direction of modern medicine is the study and revelation of biomarkers 
that in OA context would give a possibility to not only reveal the potentially irreversible changes 
in the articulate cartilage structure but also to prognosticate the speed of disease progressing. The 
searches in this branch were started already in 2006 when American society for OA biomarkers 
offered biomarkers classification «BIPED» (Burden of Disease, Investigative, Prognostic, Efficacy 
of Intervention and Diagnostic) for the widening of possibilities of OA study [16]. According to this 
classification, 5 markers of OA are separated: burden of disease (CTXII, COMP, leptin, adiponec-
tin, visfatin), prognosis (CTXII, COMP, ММР-3, ММP-1, С2М, С2С, leptin, adiponectin, visfatin), 
С-reactive protein, interleukin-6), efficacy of intervention, investigative (genetic markers) and di-
agnostic ones (CTX II, COMP, С2С, PIINP, osteocalcin, FSTL-1, PIIANP, sRAGE) [16, 17]. 
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Despite the series of researches on the study of biomarkers that potentially can be used 
from the position of diagnostic significance at OA, the problem of distinct “marker algorithm” 
remains open for today [16]. The last recommendation on this question were offered in instruc-
tions of ESCEO (The European Society for Clinical and Economic Aspects of Osteoporosis and 
Osteoarthritis) in 2012, according to which the most reliable markers of OA are the structural 
molecules or their fragments that are the constitutive components of articulate cartilage, SCB 
or synovial tunic and, according to experts, can reliably reflect the processes of degradation and 
synthesis in these tissues [18]. 
Osteocalcin (ОC) it is a main non-collagenous protein of the bone matrix that contains hy-
droxyapatite and is a structural component of the bone organic matrix [18]. It is known, that OC 
is synthesized by osteoblasts that is why its level in the blood plasma can testify about the osteo-
blasts metabolic activity, because OC concentration in blood is a result of new synthesis and not 
the release of it at the resorption of bone tissue. Alongside with it OC has calcium binding effect 
and takes part in the bone mineralization [17]. The series of researches demonstrated the increase 
of OC level in patients with OA on the background of intensification of remodeling processes and 
changes in the process of bone tissue mineralization that was associated with further osteophytosis 
progressing [19, 20]. Thus, OC can be considered as the specific marker of functional activity of 
SCB osteoblasts and the sensitive marker of the bone tissue remodeling. The data that demonstrate 
the decrease of OC level among patients with obesity and its connection with carbohydrate metab-
olism disorder are also interesting [15].
Alongside with OC there is also the series of other markers of bone metabolism that reflect 
the synthesis processes in bone tissue. For example, procollagen IC-terminal propeptide (PICP) 
that is synthesized by osteoblasts as predecessor and is a big molecule that has the partially globular 
fragment – РІСР on С-end, which structure is stabilized by bisulfite connections [4]. Entering in 
extracellular space, РІСР undergoes enzyme hydrolysis and remains in extracellular liquid and the 
mature collagen 1 molecule takes part in formation of the bone matrix. Although the ratio between 
collagen that is settled in the bone matrix and РІСР quantity that comes into the blood channel is 
theoretically equal 1, РІСР can be used for the assessment of metabolic activity of osteoblasts [21]. 
The most researches of РІСР are concentrated on the study of this marker from the positions of 
system osteoporosis, where were demonstrated the decrease of its level in the conditions of osteo-
porosis. Taking into account the fact that osteoporosis not only negatively influences the SCB state 
and is an unfavorable factor of the development and progressing of OA but is often combined with 
OA, the study of this marker from OA positions is very topical. Nevertheless the literary data as to 
the study of РІСР with OA are not enough that conditions the topicality of this work. 
The modern conception of OA therapy provides two hypothetic points on influence on OA 
pathogenetic links: anti-inflammatory therapy that is realized by the use of non-steroid anti-inflam-
matory drugs and the therapy, directed on deceleration of degradation of articulate cartilage com-
ponents and disease progressing that is realized by the use of symptomatic slow acting drugs for 
osteoarthritis – SYSADOA) [22]. At the same time the one of unsolved problems in the treatment of 
patients with OA remains the absence of pathogenetic model of influence on SCB that, according to 
the modern notions, can be the “target” at OA. Although the use of biphosphonates in patients with 
OA remains problematic, taking into account the high risks of side effects, connected with their 
use, it is expedient to study the ability of basic OA preparations to make the correcting influence 
on SCB state. According to ESCEO recommendations, symptomatic slow acting drugs are related 
to the preparations of the 1 step of OA treatment. The representative of this group is diacerein 
that demonstrated the high clinical efficacy at treatment of patients with ОА [23] at the expense of 
verified anti-inflammatory effect, conditioned by inhibition of interleukin -1 and, according to the 
results of recent research, can influence the separate catabolic and anabolic mediators of inflamma-
tion that participate in OA pathogenesis [24].
2. Aim
To assess the levels of markers of the bone synthesis and system inflammation in patients 
with OA in combination with obesity and their dynamic under the influence of basic treatment. 
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3. Materials and methods
The research included 40 women with OA, 46–78 years old (mean age is 59,8±1,5 years), 
in 31 of them was diagnosed monoosteroartritis and in 8 patients – olygoosteroathritis OA (Table 1). 
In most patients was diagnosed the II stage of ОА – 65 %, І and ІІІ stage – in 25 % and 10 % re-
spectively. The duration of disease varied from 3 to 36 years (mean duration – 10,0±1,1 years). All 
patients underwent therapy according to the local protocol of medical help for patients with OA 
that included symptomatic slow acting drug – diacerein (“Flexerin”) and symptom-modifying 
preparations – non-steroid anti-inflammatory preparations (NAIP) from the group of selective 
inhibitors of cyclooxigenase-2 (meloxicam, celecoxib and other). Patients received flexerin 
(PC “Kyiv vitamin factory”) according to the scheme: first 2 weeks – 50 mg/day with further 
increase of dose up to 100 mg/day. 
The mean body mass index (BMI) among patients was 30,6±0,7 [22,3; 39,5] kg/m2, at 
that BMI ˃29,9 kg/m2 was diagnosed in 23 patients with mean BMI value in this group of pa-
tients 33,7±0,7 [30,3; 39,5] kg/m2. To assess the influence of obesity on the bone synthesis pro-
cesses and system inflammation level all patients with OA were divided in 3 groups: patients 
with OA without obesity (n=17), patients with OA with 1 degree of obesity (n=14), patients with 
OA with 2 degree of obesity (n=9). 
Table 1
Characteristics of injury of main groups of joints among patients with OA
Joints Patients with ОА (n=40) %
Monoosteroarthritis ОА (n=31)
Knee 20 50
Hand joints 9 22,5
Hip 3 7,5
Olygoosteroarthritis ОА(n=8)
Knee+hand joints 6 15,0
Knee+hip 2 5,0
The level of osteochondral metabolism was assessed using quantitative measuring of the lev-
els of procollagen IC-terminal propeptide (РІСР), (Cloud-CloneCorp. «procollagen IC-Terminal Pro-
peptide, USA) and osteocalcin (Roche Diagnostics «N-MID Osteocalcin», Switzerland) on analyzer 
«ELECSYS 2010» by the method of immune-enzyme analysis; the level of the system inflammation 
was assessed by the level of C-reactive protein (CRP) by the method of immunoturbidimetry. The 
clinical efficacy was assessed by the dynamics of intensity levels of pain syndromes at physical load 
and at rest by the visual-analogue scale (VAS). The measuring of РІСР, osteocalcin and CRP levels 
and also the assessment of clinical effectiveness as to the decrease of pain syndrome were carried out 
twice – at the beginning and at the end of observation. The period of observation is 2 months. 
For the statistical analysis of data the descriptive statistics with calculation of the mean 
value (М), mean standard mistake (m) was used. The probability of difference was assessed by the 
parametric methods (on Student t-criterion for unrelated samples) and non-parametric ones (Pir-
son χ2 Mann-Whitney, Kholmogorov-Smirnov U-criterion). Interconnection between the studied 
parameters was revealed using the calculation of Spearmen correlation coefficient. All data are 
presented as the mean value and its mistake. The difference at р˂0,05 was considered as significant 
one. All calculations were realized in Statistica 6.0 program.
4. Results
The mean РІСР level among patients with OA was 35,8±3,7 [4,1;78,1] pg/ml, ОC – 23,8±1,6 
[8,9; 53,3] mcg/ml, CRP – 5,0±0,5 [0,7; 13,8] mg/ml. On VAS the mean pain level at load and at 
rest from the side of knee joints was– 4,1±0,34 and 5,7±0,38 points, respectively. The mean pain level 
from the side of other joint zones at rest was 3,6±0,31 points, at physical load – 5,5±0,41 points. Sta-
tistical analysis did not revealed the reliable difference between the initial levels of РІСР, ОC and 
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CRP in patients with ОА depending on BMI. Nevertheless there was demonstrated a tendency to 
the increase of PICP level among patients with ОА and 2 degree of obesity (Table 2) that exceeded 
the level among patients with OA and normal body weight by 18,7 %. The opposite tendency was 
demonstrated related to OC level – the decrease of it depending on BMI increase with maximal 
difference between patients with OA and normal body mass and obesity of 2 degree – 24,6 %. At 
that CRP level was the highest one among patients with OA and 1 degree of obesity without clear 
tendency as to the change of its level depending on BMI (Table 2).
Table 2
PICP, ostecalcin, SRP levels in patients with OA depending on presence and degree of obesity 
PICP, pg/ml Osteocalcin, mcg/ml CRP, mg/ml 
BMI ≤29,9 kg/m2 (n=17) 36,1±5,2 [5; 78,1] 25,6±2,6 [14,9; 53,3] 5,2±0,7 [0,7; 8,7]
BMI 30–34,9 kg/m2 (n=14) 29,5±6,7 [4,1; 72,0] 24,6±2,5 [14,5; 48,9] 6,3±0,8 [2,9; 13,8]
BMI 35–39,9 kg/m2 (n=9) 44,4±8,6 [8,2; 72,0] 19,3±3,0 [8,9; 33,6] 3,9±0,5 [1,8; 6,3]
Note: р˂0,05 between data in the groups of comparison 
Together with it, the direct correlation between РІСР level and BMI was revealed among 
patients with the normal body weight (r=0,62; р=0,008) (Fig. 1), whereas among patients with 
obesity the analogous correlation was established relative to CRP level and BMI (r=0,43; р=0,04) 
(Fig. 2, b) on the background of correlation of PICP and OC levels (r=0,46; р=0,03) (Fig. 2, a).
Fig. 1. Correlation between PICP level and BMI among patients with OA and normal weight
In patients with OA obesity was associated with reliably higher pain levels, both at rest and 
at physical load from the side of knee joints, with maximal intensity of pain syndrome among pa-
tients with OA and 1 degree of obesity (Table 3).
Table 3
Intensity of pain syndrome at rest and at physical load in patients with OA depending on BMI 
BMI ≤29,9 kg/m2 (n=17) BMI 30–34,9 kg/m2 (n=14) BMI 35–39,9 kg/m2 (n=9)
VAS at rest, points
Knee joints 3,4±0,5* 4,7±0,7* 4,4±0,6*
Other articulate zones 3,4±0,4 3,9±0,7 3,4±0,4
VAS at physical load, points
Knee joints 4,8±0,6* 6,5±0,5* 6,0±0,7*
Other articulate zones 5,4±0,7 5,8±0,7 5,1±0,8
Note: * – р˂0,05
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Fig. 2. Correlation between РІСР, osteocalcin, CRP levels and BMI among patients with OA in 
combination with obesity: а – correlation between РІСР and osteocalcin levels; 
b – correlation between CRP level and BMI
The role of system inflammation in the bone metabolism process at OA was assessed 
depending on the initial CRP level, according to which all patients were divided in 2 groups: 
patients with normal CRP level (≤6 mg/l), and patients with increased CRP level ˃6 mg/l 
(Table 4). Analysis of the received results did not reveal the dependence between РІСР and 
OC levels in patients with OA depending on initial CRP level. Nevertheless there was demon-
strated that the increased CRP level conditioned the tendency to the increase of РІСР level and 
decrease of OC level comparing with levels of these parameters in patients with OA and the 
normal CRP level (Table 4).
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РІСР and osteocalcin levels in patients with OA depending on CRP level at the beginning of research 
Studied parameters CRP ≤6 mg/l (n=25) CRP ˃6 mg/l (n=15) р
CRP, mg/l 3,2±0,3 [0,4; 5,9] 8,0±0,5 [6,1; 13,8] р˂0,001
РІСР, pg/ml 33,3±4,7 [4,1; 78,1] 40,4±6,2 [5,0; 72,0] р˃0,05
Osteocalcin, mcg/ml 24,8±2,1 [8,9; 53,3] 22,1 ±2,4 [12,9; 41,4] р˃0,05
The influence of medical therapy on SCB state and on the sytem inflammation level was 
assesed on the base of study of the dynamic of РІСР, ОC and CRP levels among patients with OA, 
who received “Flexerin” – main group (n=15) and among patients, who received only NAIP – con-
trol group (n=25).
Thus, among patients of the main group at the end of observation period the maxi-
mal effect as to the decrease of pain syndrome intensity was demonstrated from the side of 
knee joints, where pain at rest decreased by 37,5 % (р˂0,005) and by 39,7 % at physical load 
(р˂0,001) comparing to the initial level. The comparable effect at the end of observation period 
was attained from the side of other articulate zones, where pain syndrome at rest decreased 
by 31,3 % and by 36,4 % – at physical load (р˂0,05). The decrease of pain syndrome intensity 
among patients from the control group demonstrated also the reliable decrease as to the pain 
at rest and at physical load, that decreased by 29,3 % and 31,6 % respectively, from the side 
of knee joints at the end of 2 month of observation (р˂0,05), and from the other articulate 
zones – by 29,7 % and 27,8 % respectively (р˂0,05). 
The decrease of pain syndrome among patients from the main group was associated with the 
reliable decrease of CRP level (р=0,013) comparing with initial levels at the absense of significant 
dynamics as to РІСР and OC levels (Fig. 3).
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Instead of it, among patients of control group there was observed only tendency to the de-
crease of РІСР, ОC and CRP levels on the background of the received therapy at absence of the 
reliable difference between initial and final levels (Fig. 4).
Fig. 4. Dynamics of РІСР, osteocalcin and CRP levels among patients of the control group 
The research demonstrated that CRP level conditioned the certain features in the type of 
reacting of the bone tissues on the therapy with basic preparations (Table 5). 
Table 5
РІСР and osteocalcin levels in patients with OA depending on CRP level at the end of research 
Studied parameters CRP ≤6 mg/l (n=28) CRP ˃6 mg/l (n=12) р
CRP, mg/l 3,5±0,3 [0,6; 5,6] 7,5±0,5 [6,1; 12,0] р˂0,001
РІСР, pg/ml 36,8±4,2 [3,2; 70,6] 15,8±5,1 [2,3; 57,4] р=0,0076
Osteocalcin, mcg/ml 20,5±1,1 [11,6; 31,8] 24,3±2,4 [13,4; 38,3] р˃0,05
Thus, in the group of patients with increased CRP level was observed the reliable (р=0,0076) 
decrease of РІСР level (40,4 pg/ml vs 15,8 pg/ml) on the background of tendency to the increase of 
OC level (22,1 mcg/ml vs 24,3 mcg/ml) at the end of 2 month of observation (р˃0,05). Instead of 
it, in patients with the normal CRP level the reliable difference between the initial and final РІСР 
and OC at the present tendency to the increase of РІСР level (33,3 pg/ml vs 36,8 pg/ml) and the 
decrease of OC level (24,8 mcg/ml vs 20,5 mcg/ml) on the background of therapy with OA basic 
preparations was not demonstrated. 
5. Discussion 
The received results testify that the control of the system inflammation level at OA is a target 
not only relative to the decrease of pain syndrome but also conditions the stable state of subchondral 
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The significance of procollagen IC-terminal propeptide (РІСР) and osteocalcin (OC) as the markers 
of bone synthesis that are able to reflect metabolic processes in SCB at OA was demonstrated at the 
research. РІСР and OC levels do not demonstrated the reliable dependence from the obesity and 
system inflammation level. At the same time there was demonstrated the discordant influence of 
CRP level on PICP level in patients with OA, that determines the reliable decrease of its level under 
conditions of the increased CRP level and the tendency to the increase of the level under conditions 
of referent CRP values at the relative stability of OC levels. Thus in the conditions of control over 
the system inflammation the positive changes in the aspect of РІСР and OC levels were observed, 
characterized with the balance of catabolic and anabolic processes in SCB. 
Nevertheless the received results allow consider the inflammatory process at OA as a target 
for preservance of the bone tissue, conditioning the expedience of taking into account the ability of 
OA basic preparations to realize the controling influence on the system inflammation level. Diace-
rein that in ESCEO recommendations (2014) is related to the preparations of the 1 step of treatment 
of patients with OA provides the control on inflammation and stability of osteocalcin level that 
testifies to the balance of catabolic processes in SCB. It was not demonstrated at using NAIP. This 
advantage can be prospective in the aspect of further study of SCB state in patients with OA under 
conditions of treatment with basic preparations, recommended by international organizations that 
deal with this problem (OARSI 2014, EULAR 2003, 2007, ESCEO 2012). 
We understand that the results of our research can have certain limitations that is condi-
tioned by the little number of patients in groups of observation and the further studies of presented 
problem are needed. 
6. Conclusions
1. At OA the levels of procollagen IC-terminal propeptide (РІСР) and osteocalcin (OC) were 
not associated with obesity and did not depend on the initial CRP level at the presence of correla-
tion between РІСР level and BMI among patients with OA with the normal body weight and BMI 
and CRP level among patients with OA in combination with obesity. 
2. The absence of reliable dynamics from procollagen IC-terminal propeptide (РІСР) side 
and maintenance of the stable osteocalcin (OC) level on the background of the reliable anti-inflam-
matory effect at using diacerein (“Flexerin”) in patients with OA can testify to the compensatory 
adequacy of reparation processes in SCB.  But the tendency to the decrease of РІСР and ОC levels 
and the absence of reliable influence on the system inflammation level at using only NAIP can re-
flect decompensation in the processes of synthesis and destruction in the bone tissue with the shift 
of balance to the predominance of catabolic processes in SCB at certain comparability from the 
side of the results of analgesic effect at using diacerein and NAIP. 
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